$899 – $2,699

19th World Congress on Pharmaceutical Sciences and Innovations in Pharma In...

Event Information

Share this event

Date and Time

Location

Location

Venue will be informed to the Registered Participants

Berlin

Germany

View Map

Refund Policy

Refund Policy

No Refunds

Event description

Description

19th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry

About

Pharma Conferences 2019

Conference Name


Place


Date

Pharmaceutical Sciences Conferences 2019


Berlin, Germany



February 25-26, 2019


Following the tradition of successful Congresses held in several European countries, Dubai, Spain, Italy, India, South Africa and USA, the Organizing Committee of ConferenceSeries Ltd is pleased to invite all the participants across the globe to attend the 19th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry slated on February 25- 26, 2019 at Berlin, Germany.

The conference is a specially organized two-day event which will provide a multi-channel communication platform that brings together both “producers” and “consumers” of pharma world of the generic sector. It includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. It is a perfect platform for researchers, scientists and, delegates to share experience, foster collaborations across industry and academia, and evaluate emerging technologies across the globe.

For more details please visit- https://industry.pharmaceuticalconferences.com


Pharma Conferences | Pharmaceutical Conferences 2019 | World Pharma Conferences | Top Pharmaceutical Conferences | Pharmaceutical Sciences 2019 | Pharmaceutical Conferences | Pharma Conferences 2019 | Pharma Conferences | Pharmaceutical Conferences 2019 | World Pharma Conferences | Top Pharmaceutical Conferences | Pharmaceutical Sciences 2019 | Pharmaceutical Conferences | Pharma Conferences 2019 | Pharma Conferences | Pharmaceutical Conferences 2019 | World Pharma Conferences | Top Pharmaceutical Conferences | Pharmaceutical Sciences 2019 | Pharmaceutical Conferences | Pharma Conferences 2019 | Pharm Industry 2019 | Pharmaceutical Industry 2019 | Pharma Europe 2019

Why attend Pharmaceutical Sciences 2019:

Motives to attend:

Keynote presentation along with interactions to galvanize the scientific community.
Workshop and symposiums to reach the largest assemblage of participants from the Pharma community.
A wide track of exhibitors to showcase the new and emerging technologies.
Platform to global investment community to connect with stakeholders in Pharma sector.
Young Scientist/Investigators Award geared towards best budding young research.
Links to the political marketing resources in order to expand your business and research network.
Triumph of Awards, Certificates recognizes your commitment to your profession to encourage the nascent research.

2018 Highlights:

150+ Participation (70 Industry: 30 Academia)
10+ Keynote Speakers
50+ Plenary Speakers
20+ Exhibitors
14 Innovative Educational Sessions
5+ Workshops
B2B Meetings


Pharmaceutical Sciences 2019 has everything you need:

Open panel discussions: Providing an open forum with experts from academia and business to discuss on current challenges in Pharmaceutical Sciences & Pharma Industry, where all attendees can interact with the panel followed by highly affiliated speakers.

Speaker and poster presentations: Providing a platform to all academicians and industry professionals to share their research thoughts and findings through a speech or a poster presentation.

Editorial board meeting: Discussing on growth and development of Pharmacoeconomics: Open Access International Journals and recruiting board members and reviewers who can support the journal.

Round table meetings: Providing a platform where industry professionals meet academic experts.

Over 50+ organizations and international pavilions will be exhibiting at the Pharmaceutical Sciences 2019. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

The Pharmaceutical Sciences 2019 has everything you need, all under one roof, saving you both time and money. It is the event you cannot afford to miss!

Target Audience:

Researchers
Directors, CEO’s of Organizations
Scholars from Pharmaceutical backgrounds
PhD Scholars
Drug Delivery Technology Manufacturers
Business Development Managers
Distributors and Suppliers of Drug Delivery Technologies
Students, Professors, Researchers, and Faculty of Pharmaceutical Sciences from Universities and Medical Colleges
Researchers from Pharmaceutical Companies, Pharmacy Associations and Societies
Health professionals
Pharmacists
Business development professionals, Consultants and Pharma service providers
Quality control specialist
Graduates and post graduates in industrial pharmacy
Medical Devices Manufacturing Companies, CRO
Data Management Companies.
Pharmaceutical legislators and regulators
Chief Scientific Officers
R&D Researchers from Biosimilar and Biologics Industries
Professors, Associate Professors, Assistant Professors
Patent Attorneys
Intellectual Property Attorneys
Investment Analysts
Association, Association presidents and professionals
Noble laureates in Health Care and Medicine
Bio instruments Professionals
Bio-informatics Professionals
Software development companies
Research Institutes and members
Supply Chain companies
Manufacturing Companies
CRO and DATA management Companies
Training Institutes
Business Entrepreneurs

A two day gathering that examines the future market patterns, creative business methodologies and open doors for the development of moderate medications. Pharma pioneers want the substance and roundtable examinations, yet remain for the systems administration and air.

This meeting is formally the biggest key nonexclusive gathering in the business and will give members a thorough survey of business methodology for moderate meds.

Get your image before senior chiefs
Break into the lucrative Generic Medicines industry
Position your organization as an industry pioneer
Make deals leads and convey an arrival on venture
Connect with your objective market in the locale.

You will meet:

Board level and senior agents from nonspecific and pharmaceutical organizations
Venture banks
Business Development Leader from Pharma and Biosimilars company
Law Offices

Your chance:

Develop long-haul connections by organizing gatherings with top prospects
Talk and show thought the administration
Increment mark mindfulness and situating

Session/Tracks

The Organizing Committee of ConferenceSeries Ltd and Pharmaceutical Sciences 2019 invites all the participants across the globe to attend the 19th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry on February 25- 26, 2019 at Berlin, Germany.

Track 1: Globalized Pharma Sector

Globalized Pharma Sector is based on gaining information on changing structure of competition and increased competitiveness, lack of brand new products, despite increased investments into R&D Research and Development activities, increased importance of regulatory issues (registrations, intellectual property rights, litigations), fast consolidation and concentration of the world Pharmaceutical industry can be known as the Globalized Pharma Sector.

Track 2: Drug Discovery

In the fields of medicine, biotechnology and Pharmacology, drug discovery is the process by which new candidate medications are discovered. Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy or potency, metabolic stability (to increase the half-life), and oral bioavailability.

Track 3: Drug Development

Drug development focusses on launch of new Pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.

Track 4: Pharmaceutical Sciences

The pharmaceutical sciences combine broad range of scientific disciplines that are critical to the discovery and development of new drugs and therapies. Pharmaceutical Sciences is a dynamic and interdisciplinary field that aims to integrate fundamental principles of physical and organic chemistry, engineering, biochemistry, and biology to understand how to optimize delivery of drugs to the body and translate this integrated understanding into new and improved therapies against human disease. At the many of institutes internationally recognized faculty contribute to the field through inquiry into the underlying mechanisms of drug interactions with the human body and development of advanced synthetic or biologically-derived materials that can modulate these interactions in pursuit of better and safer therapies and drug products.

Track 5: Drug Targeting and Design

The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to predict the conformation of the small molecule and to model conformational changes in the biological target that may occur when the small molecule binds to it. The therapeutic response of a drug depends upon the interaction of drug molecules with cell on cell membrane related biological events at receptor sites in concentration dependent manner.

Selective and effective localization of the pharmacologically-active moiety at preidentified target(s) in therapeutic concentration, while restricting its access to non-target(s) normal cellular linings, thus minimizing toxic effects and maximizing the therapeutic index accounts from effective and efficient drug delivery.

Molecular mechanics methods may also be used to provide semi-quantitative prediction of the binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity estimates. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by fitting experimental affinities to computationally derived interaction energies between the small molecule and the target.

Ideally, the computational method will be able to predict affinity before a compound is synthesized and hence in theory only one compound needs to be synthesized, saving enormous time and cost. The reality is that present computational methods are imperfect and provide, at best, only qualitatively accurate estimates of affinity. In practice it still takes several iterations of design, synthesis, and testing before an optimal drug is discovered. Computational methods have accelerated discovery by reducing the number of iterations required and have often provided novel structures.

Track 6: Pharmaceutical Nanotechnology

Pharmaceutical Nanotechnology deals with emerging new technologies for developing customized solutions for drug delivery systems. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. In addition to this the drug delivery system also allows the drug to bind to its target receptor and influence that receptor’s signaling and activity. Pharmaceutical nanotechnology embraces applications of Nano science to pharmacy as nanomaterial and as devices like drug delivery, diagnostic, imaging and biosensor.
and Nanotechnology, Journal of Nanopharmaceutics and Drug Delivery and Journal of Nanotechnology

Track 7: Drug Delivery Technologies

A route of administration is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).

Routes of administration are usually classified by application location (or exposition). The route or course the active substance takes from application location to the location where it has its target effect is usually rather a matter of pharmacokinetics (concerning the processes of uptake, distribution, and elimination of drugs). Nevertheless, some routes, especially the transdermal or transmucosal routes are commonly referred to routes of administration. The location of the target effect of active substances is usually rather a matter of pharmacodynamics (concerning e.g. the physiological effects of drugs). Furthermore, there is also a classification of routes of administration that basically distinguishes whether the effect is local (in "topical" administration) or systemic (in "enteral" or "parenteral" administration).

Track 8: Regulatory Requirements for Pharmaceuticals

The area unit variety of motives for extending the merchandise development outside of the mature, developed economies (e.g. the EU and therefore the US) and most of them have faith in the high population and market potential of rising markets. FDA guidance for clinical investigations and Pharmaceutical development goes a lot of and a lot of international within the direction of rising markets that tend to supply solutions for the patient achievement and overall development prices and timelines.

Track 9: Smart Drug Delivery Systems

Smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on Nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages.

Targeted drug delivery systems have been developed to optimize regenerative techniques. The system is based on a method that delivers a certain amount of a therapeutic agent for a prolonged period of time to a targeted diseased area within the body. This helps maintain the required plasma and tissue drug levels in the body, thereby preventing any damage to the healthy tissue via the drug. The drug delivery system is highly integrated and requires various disciplines, such as chemists, biologists, and engineers, to join forces to optimize this system.

Track 10: Purpose and Principles of GMP

Good Manufacturing Practices quality of drugs is essentially the responsibility of manufacturers. GMP Guidelines are means to assure this very quality of drugs. CGMP refers to the Current Good Manufacturing Practice regulations enforced by the US Food and Drug Administration (FDA). CGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities. Adherence to the CGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. GMP is actually good common sense quality management quality assurance GMP production and quality control.

Track 11: Nanotechnology in Drug Delivery

Nanotechnology has finally and firmly entered the realm of drug delivery. Performances of intelligent drug delivery systems are continuously improved with the purpose to maximize therapeutic activity and to minimize undesirable side-effects. The primary goals for research of nano-bio-technologies in drug delivery include:

More specific drug targeting and delivery,
Reduction in toxicity while maintaining therapeutic effects,
Greater safety and biocompatibility, and
Faster development of new safe medicines

Pharmaceutical conferences offers presentations by researchers from a number of disciplines, from the life sciences to engineering, who will address a range of topics including peptide and protein delivery, gene delivery, cell delivery, vaccines, transdermals, pulmonary delivery, new materials, and other subjects, from varied disciplines while focusing on the central theme of drug delivery.

Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, Peptisyntha Inc. and Lonza Inc.

The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.

Track 12: Generics versus Big Pharma

Yet over the past decade in particular, most of the Big Pharma have adopted small molecule generics in one shape or form into their overall business model. And many of them openly talk about the “innovation headroom” that a healthy low-priced generics market enables i.e. the money saved on off-patent drugs can be used to fund high-priced new innovations. They have recognized that they cannot fight the realities of aging populations and healthcare economics.

Track 13: Clinical Pharmacy and Therapeutics

Drug absorption is set by the Drug’s chemistry properties, Formulation, and route of administration. Dosage forms (e.g. tablets, capsules, solutions), consisting of the drug and alternative ingredients, square measure developed to lean by numerous routes (e.g. oral, buccal, sublingual, rectal, parenteral, topical, inhalational). In spite of the route of administration, medicine should be in answer to be absorbed.

Track 14: R&D Advancement: Road to New Medicines

Big pharmaceutical companies develop new business models to cope with the innovation crisis (patent loss, drying up of pipelines) and to improve their productivity in R&D and innovation. These pressures led big players to transform or reinvent their business models to sustain value creation from R&D and innovation. However, to our knowledge, there is still a lack of understanding regarding the “strategic alignment” of these organizational changes and on how they are perceived by organizational members.

Track 15: Digital Pharma

Some of the people believes that digital capabilities are not only critical to Pharmaceutical companies’ ability to improve the way they roll out new products, but to increasing the Pharmaceutical industry’s contribution to health care by enabling it to provide innovative services to improve patients’ outcomes. In order to increase the perceived value of Pharma within the health care system, the industry is striving to respond to the needs of all stakeholders: health care professionals, patients and payors. In the meantime, the culture of Pharmaceutical companies is shifting from one of separate departments working vertically to one that is cross functional.

Track 16: Pharmaceutical Engineering

Drug Manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be broken down into a series of unit operations such as Milling, Granulation, Coating, Tablet pressing and others. Statistics are critical to the Pharmaceutical industry, from clinical operations through manufacturing. However, clinical and manufacturing statistics represent entirely different worlds. Where they might be well staffed on the clinical side, some Pharmaceutical companies today aren’t hiring qualified staff to analyze operations data, resulting in misapplied tools, inadequate CAPAs and superficial root cause analysis, all of which lead to financial loss and noncompliance.

Track 17: Temper-Evident Pharmaceutical Packaging

Packaging plays an important role in providing protection, presentation, convenience, identification information, and compliance of a product during storage, transportation, display and until the product is safely consumed. Packaging may be considered as a system by which the product safely reaches from producer to consumer. The track mainly focuses on recent advances in packaging technology and packaging material. Many types of symbols for package labeling should be nationally and internationally standardized. Packaging symbols represent product certifications, trademarks and proof of purchase.

Track 18: Pharmaceutical Supply Chain Optimization

Quality cannot be adequately assured by in-process and finished inspections and testing but it should be built in to the manufacturing process. These processes should be controlled in order that the finished product meets all quality specifications. Validation is one of the important steps in achieving and maintaining the quality of the final product. If each step of production process is validated we can assure that the final product is of the best quality. Validation of the individual steps of the processes is called the process validation. Different dosage forms have different validation protocols. Process Validation is one of the important steps in achieving and maintaining the quality of final product. It gives a higher degree of assurance.

Track 19: Pharmaceutical Process Validation

Pharmaceutical Process Validation is the most important and recognized parameters of CGMPs. Quality cannot be adequately assured by in-process and finished inspections and testing but it should be built in to the manufacturing process. These processes should be controlled in order that the finished product meets all quality specifications. Validation is one of the important steps in achieving and maintaining the quality of the final product. The requirement of process validation appears of the quality system (QS) regulation. The goal of a quality system is to consistently produce products that are fit for their intended use.

Track 20: Medico Marketing

Medico-Marketing focusses on exchange of drug information among drug manufacturing company and the recommending doctor, Nurse, Pharmacist or with the end user. The intention behind this data exchange is to describe the Pharmaceutical Company’s products and how it will benefit the patient community in diagnosis or management of the human ailments.

Track 21: Pharma and Biotech Financial Outlook

The downturn in the global economy has forced Pharmaceutical and life sciences companies to focus on cost-saving initiatives, putting stress on finance departments. Although optimizing costs will always be important, reinvigorating R&D will most likely be a top strategic initiative for these companies as well. Most big Pharmaceutical companies are under competitive pressure from generic drug maker’s pressure that will become more intense as an increasing number of patents for “blockbuster” drugs expire during the next few years.

Track 22: Entrepreneurs Investment Meet

A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment.

AGENDA

SCIENTIFIC PROGRAM
Monday, 25th February DAY 1

08:30-09:00 Registrations
09:00-09:30 Introduction
09:30-09:50 COFFEE BREAK
09:50-11:50
Meeting Hall 01 KEYNOTE LECTURES
MEETING HALL 01 MEETING HALL 02
11:50-13:10 Talks On:
Globalized Pharma Sector
Talks On:
Drug Discovery
Pharma and Biotech Financial Outlook Drug Targeting and Design
Digital Pharma Drug Delivery Technologies
Generics versus Big Pharma Smart Drug Delivery Systems
Medico Marketing Entrepreneurs Investment Meet
13:10-13:15 GROUP PHOTO
13:15-14:00 LUNCH BREAK
MEETING HALL 01 MEETING HALL 02
14:00-16:00 Talks On: Drug Development Talks On: Pharmaceutical Sciences
Discovery and Development Pharma and Biotech Financial Outlook
Preclinical Research Pharmaceutical Process Validation
Clinical Research Pharmaceutical Supply Chain Optimization
Drug Development Companies Tamper-Evident Pharmaceutical Packaging
Drug Characterisation Pharmaceutical Engineering
16:00-16:20 COFFEE BREAK
MEETING HALL 01 (16:20-17:00) MEETING HALL 01 (17:00-18:00)
Young Researchers in
Pharmaceutical Sciences 2019 Workshop

SCIENTIFIC PROGRAM
Tuesday, 26th February DAY 2

09:00-10:30
Meeting Hall 01 KEYNOTE LECTURES
10:30-10:50 COFFEE BREAK
MEETING HALL 01 MEETING HALL 02
10:50-12:50 Talks On:
Pharmaceutical Nanotechnology
Talks On:
Purpose and Principles of GMP
Characterization of Pharmaceutical
Nanotools GMP/GCP Interface & GMP audits
Challenges to Pharmaceutical GMP Requirements & Standards
Nanotechnology in Drug Delivery Tamper-Evident Pharmaceutical Packaging
Pharmaceutical Nanotechnology Clinical Pharmacy and Therapeutics
Future Prospects of Pharmaceutical
Nanotechnology FDA Good Manufacturing Practices
12:50-13:35 LUNCH BREAK
MEETING HALL 01 MEETING HALL 02
13:35-15:55 Talks On:
Clinical Pharmacy and Therapeutics
Talks On:
Regulatory Requirements for Pharmaceuticals
Clinical trials and drug information Information on Compounding
Outcome research and pharmacoeconomic
studies Drug Compliance Programs
Clinical case studies FDA guidance for clinical investigations
Role of pharmacist in communicating and
counseling patients Nicotine-Containing Products
Clinical genomics and proteomics Newly Added Guidance Documents
15:55-16:15 COFFEE BREAK
MEETING HALL 01 (16:15-17:00) MEETING HALL 01 (17:00-18:00)
Poster Presentations Workshop

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:
- Multiple participant discounts
- Price quotations or visa invitation letters
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)
- Event sponsorship

NO REFUNDS ALLOWED ON REGISTRATIONS
Prices may go up any time. Service fees included in pricing.
-----------------------------------------------------------------
This event is brought to you by:
Conference Series - NewYorkEventsList
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com
-----------------------------------------------------------------

VIO181214CRE

Share with friends

Date and Time

Location

Venue will be informed to the Registered Participants

Berlin

Germany

View Map

Refund Policy

No Refunds

Save This Event

Event Saved